RAFFA WEALTH MANAGEMENT, LLC’s Protagonist Therapeutics PTGX Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.36K	Hold	60	–	–	﹤0.01%	502
2026 Q1	$6.32K	Hold	60	–	–	﹤0.01%	484
2025 Q4	$5.24K	Hold	60	–	–	﹤0.01%	512
2025 Q3	$3.99K	Hold	60	–	–	﹤0.01%	529
2025 Q2	$3.32K	Buy	+60	New	+$2.88K	﹤0.01%	582

Other funds holding PTGX

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's PTGX Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 60 shares worth $7.36K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 59 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

RAFFA WEALTH MANAGEMENT, LLC held 60 shares of Protagonist Therapeutics worth $7.36K as of Q2 2026.
RAFFA WEALTH MANAGEMENT, LLC left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #502 holding.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
59 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.